New drug firsekibart takes on anakinra in rare inflammatory disease trial

NCT ID NCT07191444

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times

Summary

This study compares two medications, firsekibart and anakinra, to see which works better and is safer for people with Adult-Onset Still's disease (AOSD), a rare inflammatory condition. About 20 adults aged 18 to 75 with confirmed AOSD will take one of the two drugs. The main goal is to see how many achieve inactive disease (no symptoms and normal blood markers) after 24 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STILL'S DISEASE, ADULT-ONSET are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

STILL'S DISEASE, ADULT-ONSET